Generic Drug 180-Day Exclusivity Provisions: Hatch Seeks CBO Score

Sen. Orrin Hatch (R-Utah) wants the Congressional Budget Office to help him make the case that 180-day generic drug exclusivity provisions in the Senate and House Medicare bills need revision